Published in ESMO Open on March 17, 2016
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (BOOST) | NCT01405573
Screening, Treatment, and Eradication of Hep C | NCT05071261
Statins and the Risk of Cirrhosis in Chronic Hepatitis B Patients. Am J Gastroenterol (2016) 0.95
The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS One (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Hepatocellular carcinoma. Lancet (2012) 18.09
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 14.03
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Cholangiocarcinoma. Lancet (2005) 6.01
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2010) 5.78
EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol (2015) 5.75
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 5.70
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
The survival benefit of liver transplantation. Am J Transplant (2005) 5.08
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol (2015) 4.91
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol (2004) 4.39
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol (2013) 4.05
Gastric cancer treatment guidelines in Japan. Gastric Cancer (2002) 3.81
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl (2002) 3.44
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg (2000) 3.07
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol (2013) 2.88
Alcohol and cancer. Alcohol Alcohol (2004) 2.82
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer (2010) 2.82
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology (1991) 2.75
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl (2003) 2.68
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Reactivation of hepatitis B. Hepatology (2009) 2.46
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol (2010) 2.46
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38
The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology (2004) 2.36
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl (2011) 2.33
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol (2010) 2.31
Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology (2009) 2.25
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist (2009) 2.23
Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology (1998) 2.19
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol (2009) 2.17
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer (2009) 2.13
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg (2008) 2.10
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev (2010) 2.09
Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci (1986) 2.07
Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) (2008) 2.04
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut (2004) 2.03
Hepatotoxicity of chemotherapy. Oncologist (2001) 2.02
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol (2014) 2.01
Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg (1984) 1.97
Epidemiology of alcoholic liver disease. Semin Liver Dis (1988) 1.96
Complications of cirrhosis. I. Portal hypertension. J Hepatol (2000) 1.96
Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery (1997) 1.88
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.87
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther (2011) 1.85
Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol (2008) 1.85
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int (2007) 1.80
Gemcitabine--a safety review. Anticancer Drugs (1998) 1.74
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
Hepatic fibrosis. Curr Opin Gastroenterol (2009) 1.67
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol (2014) 1.67
Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol (2000) 1.66
Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol (2007) 1.65
Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J (2006) 1.65
Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg (2005) 1.65
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology (2010) 1.64